SCHEMBL468726

SCHEMBL468726

CCC[C@H](NC(C)=O)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
KDM4E B2RXH2 1/20 0.59
THRB P10828 1/20 0.59
ALOX15 P16050 1/20 0.59
NFKB1 P19838 1/20 0.59
PTGS2 P35354 1/20 0.59
THPO P40225 1/20 0.59
RECQL P46063 1/20 0.59
BLM P54132 1/20 0.59
ALDH1A1 P00352 2/20 0.57
GNPAT O15228 2/20 0.47
FPR2 P25090 1/20 0.47
CHRM1 P11229 1/20 0.46
AKR1A1 P14550 1/20 0.46
CHRM3 P20309 1/20 0.46
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46
ADRA1A P35348 1/20 0.46
HRH1 P35367 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL468725 1.00 MAPT (0.59) MAPTSMN1; SMN2KDM4ETHRBALOX15
SCHEMBL16748603 1.00 MAPT (0.59) MAPTSMN1; SMN2KDM4ETHRBALOX15
Ammonia Solution, Strong SCHEMBL27786825 0.98 MAPT (0.57) MAPTSMN1; SMN2KDM4ETHRBALOX15
Ammonia Solution, Strong SCHEMBL27786823 0.98 MAPT (0.57) MAPTSMN1; SMN2KDM4ETHRBALOX15
SCHEMBL7767842 0.92 GNPAT (0.54) MAPTSMN1; SMN2KDM4ETHRBALOX15
SCHEMBL7767844 0.92 GNPAT (0.54) MAPTSMN1; SMN2KDM4ETHRBALOX15
SCHEMBL15958209 0.89 NOD1 (0.61) MAPTSMN1; SMN2KDM4ETHRBALOX15
SCHEMBL12064031 0.87 SMN1; SMN2 (0.55) MAPTSMN1; SMN2KDM4ETHRBALOX15
SCHEMBL137690 0.87 SMN1; SMN2 (0.55) MAPTSMN1; SMN2KDM4ETHRBALOX15
SCHEMBL243250 0.87 SMN1; SMN2 (0.55) MAPTSMN1; SMN2KDM4ETHRBALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118620880-A Enzyme composition and application thereof in preparation of L-norvaline 长兴制药股份有限公司 2024-09-10 CN claimed
EP-3039068-B1 MOISTURE CURABLE COMPOUND WITH AMINO ACIDS MOMENTIVE PERFORMANCE MAT INC (US) 2020-12-16 EP claimed
US-9914809-B2 Moisture curable composition with amino acids MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2018-03-13 US claimed
US-20160200880-A1 MOISTURE CURABLE COMPOSITION WITH AMINO ACIDS MOMENTIVE PERFORMANCE MATERIALS INC. 2016-07-14 US claimed
EP-3039068-A1 MOISTURE CURABLE COMPOUND WITH AMINO ACIDS Momentive Performance Materials Inc. (US) 2016-07-06 EP claimed
WO-2015031712-A1 MOISTURE CURABLE COMPOUND WITH AMINO ACIDS MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2015-03-05 WO claimed
US-RE44302-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use YU RUEY J (US) 2013-06-18 US claimed
US-RE44017-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use YU RUEY J (US) 2013-02-19 US claimed
US-RE42902-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use TRISTRATA, INC. (US) 2011-11-08 US claimed
US-RE41339-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use TRISTRATA, INC. (US) 2010-05-18 US claimed
US-RE41278-E1 N-acetyl aldosamines and related N-acetyl compounds, and their topical use TRISTRATA, INC. 2010-04-27 US claimed
EP-2080504-A2 Topical composition comprising n-acetylaldosamines or n-acetylamino acids Yu, Ruey J. (US) 2009-07-22 EP claimed
EP-1639994-A2 Topical composition comprising N-acetylaldosamines or N-acetylamino acids Yu, Ruey J., Dr. (US) 2006-03-29 EP claimed
EP-1570840-A2 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS Yu, Ruey J., Dr. (US) 2005-09-07 EP claimed
US-6524593-B1 Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails TRISTRATA, INC. 2003-02-25 US claimed
EP-1143925-A1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS Yu, Ruey J., Dr. (US) 2001-10-17 EP claimed
US-6159485-A COSMETICS; SKIN DISORDERS YUGENIC LIMITED PARTNERSHIP (US) 2000-12-12 US claimed
WO-2000040217-B1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS YUGENIC LIMITED PARTNERSHIP (US) 2000-10-05 WO claimed
WO-2000040217-A1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS YUGENIC LIMITED PARTNERSHIP (US) 2000-07-13 WO claimed
WO-2025123055-A1 NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND ASSOCIATED METHODS FOR MODULATING WEIGHT GAIN ENDEVICA BIO, INC. (US) 2025-06-12 WO disclosed
CN-118947817-A Application of xylo-oligosaccharide in regulating rumen flora and metabolites of ruminants 宁夏大学 2024-11-15 CN disclosed
CN-118620880-A Enzyme composition and application thereof in preparation of L-norvaline 长兴制药股份有限公司 2024-09-10 CN disclosed
CN-118620880-A Enzyme composition and application thereof in preparation of L-norvaline 长兴制药股份有限公司 2024-09-10 CN disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 EP disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 US disclosed
CN-116829949-A Compositions for detecting or measuring analytes 伯蒂斯有限公司 2023-09-29 CN disclosed
WO-2023075435-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE 주식회사 베르티스 2023-05-04 WO disclosed
US-11629171-B2 Beta-hairpin peptidomimetics SPEXIS AG (CH) 2023-04-18 US disclosed
US-20220283131-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS CO., LTD. (KR) 2022-09-08 US disclosed
WO-2022050529-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE ㈜베르티스 2022-03-10 WO disclosed
EP-2311452-B2 Topical composition comprising n-acetyl glucosamine YU RUEY J (US) 2020-12-30 EP disclosed
EP-3039068-B1 MOISTURE CURABLE COMPOUND WITH AMINO ACIDS MOMENTIVE PERFORMANCE MAT INC (US) 2020-12-16 EP disclosed
US-9914809-B2 Moisture curable composition with amino acids MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2018-03-13 US disclosed
US-20170095475-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE CAR LLC (BM) 2017-04-06 US disclosed
US-20160200880-A1 MOISTURE CURABLE COMPOSITION WITH AMINO ACIDS MOMENTIVE PERFORMANCE MATERIALS INC. 2016-07-14 US disclosed
EP-3039068-A1 MOISTURE CURABLE COMPOUND WITH AMINO ACIDS Momentive Performance Materials Inc. (US) 2016-07-06 EP disclosed
WO-2015031712-A1 MOISTURE CURABLE COMPOUND WITH AMINO ACIDS MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2015-03-05 WO disclosed
EP-2311452-B9 Topical composition comprising n-acetyl glucosamine YU RUEY J (US) 2014-12-24 EP disclosed
EP-1882684-B1 PYRROLIDINE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2014-12-10 EP disclosed
US-8669234-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2014-03-11 US disclosed
US-RE44302-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use YU RUEY J (US) 2013-06-18 US disclosed
US-RE44017-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use YU RUEY J (US) 2013-02-19 US disclosed
US-20120264711-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-10-18 US disclosed
US-RE42902-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use TRISTRATA, INC. (US) 2011-11-08 US disclosed
EP-2311452-A1 Topical composition comprising n-acetyl glucosamine Yu, Ruey J. (US) 2011-04-20 EP disclosed
US-RE41339-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use TRISTRATA, INC. (US) 2010-05-18 US disclosed
US-RE41278-E1 N-acetyl aldosamines and related N-acetyl compounds, and their topical use TRISTRATA, INC. 2010-04-27 US disclosed
US-7585886-B2 Pyrrolidine derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2009-09-08 US disclosed
US-7585886-B2 Pyrrolidine derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2009-09-08 US disclosed
EP-2080504-A2 Topical composition comprising n-acetylaldosamines or n-acetylamino acids Yu, Ruey J. (US) 2009-07-22 EP disclosed
EP-1570840-B1 Topical composition comprising n-acetylamino acids YU RUEY J (US) 2009-04-01 EP disclosed
US-20090062366-A1 Pyrrolidine derivative or salt thereof ASTELLAS PHARAMA INC. (JP) 2009-03-05 US disclosed
US-20090062366-A1 Pyrrolidine derivative or salt thereof ASTELLAS PHARAMA INC. (JP) 2009-03-05 US disclosed
CN-100374412-C Method for amide carbonylation reaction in ion liquid UNIV ZHEJIANG (CN) 2008-03-12 CN disclosed
CN-1865235-A Method for amide carbonylation reaction in ion liquid UNIV ZHEJIANG (CN) 2006-11-22 CN disclosed
EP-1639994-A2 Topical composition comprising N-acetylaldosamines or N-acetylamino acids Yu, Ruey J., Dr. (US) 2006-03-29 EP disclosed
EP-1570840-A2 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS Yu, Ruey J., Dr. (US) 2005-09-07 EP disclosed
EP-0873290-B1 PROCESS FOR RACEMIZATION OF N-ACETYL-D(L)-ALPHA-AMINOCARBOXYLIC ACIDS DEGUSSA (DE) 2003-10-01 EP disclosed
US-6524593-B1 Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails TRISTRATA, INC. 2003-02-25 US disclosed
EP-0876329-B1 PROCESS FOR THE PRODUCTION OF N-ACETYL-D,L-ALPHA-AMINOCARBOXYLIC ACIDS DEGUSSA (DE) 2001-07-18 EP disclosed
EP-0874801-B1 PROCESS FOR OBTAINING OPTICALLY ACTIVE L-ALPHA-AMINOCARBOXYLIC ACIDS FROM CORRESPONDING RACEMIC D,L-ALPHA-AMINOCARBOXYLIC ACIDS DEGUSSA (DE) 2001-06-13 EP disclosed
US-6159485-A COSMETICS; SKIN DISORDERS YUGENIC LIMITED PARTNERSHIP (US) 2000-12-12 US disclosed
US-6114163-A ACETYLATING RACEMIC MIXTURE, NEUTRALIZING SOLUTION, DEACETYLING USING STEREOSPECIFIC ACYLASE TO PRODUCE L-STEREOISOMERS, SEPARATING OUT WANTED PRODUCT, ADJUSTING SOLUTION, RACEMIZING MIXTURE, AND DEACETYLATING AGAIN DEGUSSA AKTIENGESELLSCHAFT (DE) 2000-09-05 US disclosed
US-6080887-A HEATING A MIXTURE COMPRISING THE RACEMIC MIXTURE WITH AT LEAST ONE ALKALI OR ALKALINE EARTH SALT OF N-ACETYL-D(L)-.ALPHA.-AMINO CARBOXYLIC ACID AND ACETIC ANHYDRIDE UNDER NON-AQUEOUS CONDITIONS DEGUSSA AKTIENGESELLSCHAFT (DE) 2000-06-27 US disclosed
EP-0876329-A1 PROCESS FOR THE PRODUCTION OF N-ACETYL-D,L-ALPHA-AMINOCARBOXYLIC ACIDS Degussa Aktiengesellschaft (DE) 1998-11-11 EP disclosed
EP-0874801-A1 PROCESS FOR OBTAINING OPTICALLY ACTIVE L-ALPHA-AMINOCARBOXYLIC ACIDS FROM CORRESPONDING RACEMIC D,L-ALPHA-AMINOCARBOXYLIC ACIDS Degussa Aktiengesellschaft (DE) 1998-11-04 EP disclosed
EP-0873290-A1 PROCESS FOR RACEMIZATION OF N-ACETYL-D(L)-ALPHA-AMINOCARBOXYLIC ACIDS Degussa Aktiengesellschaft (DE) 1998-10-28 EP disclosed
WO-1997021667-A1 PROCESS FOR THE PRODUCTION OF N-ACETYL-D,L-ALPHA-AMINOCARBOXYLIC ACIDS DEGUSSA AKTIENGESELLSCHAFT (DE) 1997-06-19 WO disclosed
WO-1997021650-A1 PROCESS FOR RACEMIZATION OF N-ACETYL-D(L)-ALPHA-AMINOCARBOXYLIC ACIDS DEGUSSA AKTIENGESELLSCHAFT (DE) 1997-06-19 WO disclosed
WO-1997021663-A1 PROCESS FOR OBTAINING OPTICALLY ACTIVE L-ALPHA-AMINOCARBOXYLIC ACIDS FROM CORRESPONDING RACEMIC D,L-ALPHA-AMINOCARBOXYLIC ACIDS DEGUSSA AKTIENGESELLSCHAFT (DE) 1997-06-19 WO disclosed
US-4497964-A CARBONYLATION, HYDROGENATION SAGAMI CHEMICAL RESEARCH CENTER (JP) 1985-02-05 US disclosed
US-4497964-A CARBONYLATION, HYDROGENATION SAGAMI CHEMICAL RESEARCH CENTER (JP) 1985-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264711-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 MAPT 2923/4885SMN1; SMN2 1564/4885KDM4E 2496/4885
US-20090062366-A1 Pyrrolidine derivative or salt thereof CASR, CYP2R1, PTH1R MAPT 4566/4885SMN1; SMN2 3959/4885KDM4E 2755/4885
US-11629171-B2 Beta-hairpin peptidomimetics POLL, POLQ, HBZ MAPT 3326/4885SMN1; SMN2 4075/4885KDM4E 3552/4885
US-20170095475-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 MAPT 1888/4885SMN1; SMN2 2352/4885KDM4E 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.